Medicenna Therapeutics Corp.
Biotechnology ResearchCanada11-50 Employees
Medicenna is a clinical-stage immunotherapy company pioneering next-generation Superkines - engineered cytokines designed to overcome the limitations of other cytokines and unlock new treatment opportunities in oncology, immunology, and inflammatory diseases. Our mission is to develop life-changing immunotherapies that transform people's lives and deliver the best possible patient outcomes. Our Superkine™ BiSKIT™ and T-MASK™ platforms create novel and highly selective Superkines with best-in-class potential and/or first-in-class features, leveraging validated biology and innovative protein and antibody engineering. Our lead therapies in development are: Bizaxofusp: A Phase-3 ready immunotherapy for the deadliest form of brain cancer, glioblastoma. This is a truly aggressive & devastating disease for patients who typically live 6-9 months at relapse, with no new therapies in decades. Medicenna's program showed doubling of median overall survival in the Phase 2b trial, bringing hope and months of meaningful time to patients with brain cancer. Medicenna's IL-2 program is a best-in-class IL-2 agonist for metastatic/advanced cancers that have failed other therapies. It is currently being evaluated in a global Phase 1/2 study. This class of therapies has significant potential for patients with many forms of cancer as it trains and builds your immune system to fight off cancer. Medicenna's most advanced clinical stage program is a PD-1 x IL-2 bispecific, which aims to target cancers which express IL-13Rα2. These cancers do not typically respond to other therapies so there is a large unmet need for approximately ~2M patients annually every year. Medicenna also has early stage programs in development for autoimmune diseases and chronic inflammatory diseases like asthma and COPD.
1-888-653-2347 
support@leadiq.com 
